Trial Profile
Retrospective study of osimertinib in patients with NSCLC who harbor the EGFR T790M mutation after failure of initial EGFR-TKI treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2018 New trial record
- 01 Sep 2018 Results published in the Anticancer Research